

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Gen KONDOH : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2005_0733A
Filed April 28, 2005 :
ANGIOTENSIN-CONVERTING ENZYME
CONTAINING MEDICINE
[Corresponding to PCT/JP2003/013851
Filed October 29, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP2003/013851; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Gen KONDOH

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
April 28, 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 28, 2005

ATTY DOCKET NO.
2005_0733ASERIAL NO.
NEW

10/532986

APPLICANT
Gen KONDOHFILING DATE
April 28, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AC	91/354	1/1991	WO			
	AD	2001-316287	11/2001	JP			
	AE	95/32725	12/1995	WO			
	AF						
	AG						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	H. Kondo, "Mouse Seishoku Saibo GPI Anchor-gata Tanpakushitsu Yuri Inshi no Tanri to Kino Kaiseki", Seishoku Saibo no Seigyo Kiko to Hassei Kogaku, Heisei 11-14, Nendo, No. 11234101, pp. 69-72.
	AI	E. Jaspard et al., "Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides", J. Biol. Chem., 1993, Vol. 268, No. 13, pp. 9496-9503
	AJ	L. Wei et al., "The two homologous domains of human angiotensin I-converting enzyme are both catalytically active", J. Biol. Chem., 1991, Vol. 266, No. 14, pp. 9002-9008.
	AK	L. Wei et al., "The two homologous domain of human angiotensin I-converting enzyme interact differently with competitive inhibitors", J. Biol. Chem., 1992, Vol. 267, No. 19, pp. 13398-13405.
	AL	S. Pang et al., "Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain Shedding", Biochem. J., 2001, Vol. 358, (Pt 1), pp. 185-192.
	AM	B. Maric et al., "Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors", J. Biol. Chem., 2000, Vol. 275, No. 21, pp. 16110-16118.
	AN	S. Pang et al., "The ectodomain of angiotensin converting enzyme does not dictate sensitivity to sacretase cleavage", Biochemical Society transactions, 2000, Vol. 28, No. 5, p. A262.

EXAMINER

DATE CONSIDERED

JCT2 Rec'd PCT/PTC 28 APR 2005

FORM PTO 1449 (modified)

ATTY DOCKET NO.
2005_0733ASERIAL NO.
NEW

10/532986

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 28, 2005

APPLICANT
Gen KONDOHFILING DATE
April 28, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BC						
	BD						
	BE						
	BF						
	BG						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BH	Chemical Abstract, 1995, Vol. 123, Abstract No. 330713, abstract & A. Israel et al., "Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal modulla", Brain Research Bulletin, 1995, Vol. 38, No. 5, pp. 441-446.
	BI	Chemical Abstract, 1993, Vol. 118, Abstract No. 252487, abstract & M. Raizada et al., "Increased angiotensin II type-1 gene expression in neuronal cultures from spontaneously hypertensive rats", 1993, Vol. 132, No. 4, pp. 1715-1722.
	BJ	Chemical Abstract, 1989, Vol. 113, Abstract No. 126431, abstract & A. J. Robinson-White et al., "Inhibition of inositol phospholipid hydrolysis in endothelial cells by pentobarbital", European J. Pharmacol., Molecular Pharmacology Section, 1989, Vol. 172, No. 3, pp. 291-303.
	BK	
	BL	
	BM	
	BN	

EXAMINER

DATE CONSIDERED